Mobile Button Search>

CSR

Highlights of 2019

The mission of PharmaEssentia is to provide comprehensive R&D, innovative and breakthrough drugs to patients in need to solve their suffering and improve their lives and health. Upholding our sense of purpose, after more than 10 years of efforts to develop our innovative drug, the Ropeginterferon alfa-2b (P1101), we finally launched it on the EU market in 2019. The Company upholds its original purpose and provides drugs to patients with Polycythemia Vera (PV) at a reasonable and affordable price considering the overall local economic conditions and the financial ability of patients. In the next 10 years, we will unremittingly devote ourselves to the development of new drugs. Moreover, through the access plan, we will continue to ensure the “accessibility” of new drugs for patients around the world to meet their disease treatment needs and reduce the accessibility gap around the world; the “affordability” of new drugs to help patients obtain medicines at reasonable, fair and affordable prices; and the “availability” of new drugs to promote easier access to the drugs needed by patients in economically disadvantaged countries. Starting from our core capabilities, we create sustainable shared value with stakeholders, and promote the health and well-being of all mankind.

Access to medicine strategies
Innovative medicine - solving unmet medical needs
Responsible and transparent intellectual property right strategies
A Stable, safe and high quality drug supply chain
Leading the industrial development
Name Download
2019 CSR Report